Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes

AmgenThe Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures for medication reimbursement.

"I look forward to this collaboration providing valuable insights that will help improve patient outcomes and save money. It fully aligns with our goal to foster collaboration among public and private individuals and entities to build a responsive health care system for Oklahoma," said Nancy Nesser, J.D., Pharm.D., OHCA Pharmacy director.

The parties intend for initial research projects to use de-identified claims data to gain insights about medication adherence, missed diagnoses, heightened disease risk and other clinical indicators in Oklahoma's SoonerCare population. Disease states of special interest to each participant include autoimmune diseases, bone health/osteoporosis, migraine and oncology care. The expectation is that findings from the research will help support the development of preventive measures - for instance, identifying post fracture patients and working to educate them on the importance of disease management. In many cases, the cost of preventive therapy is a fraction of the cost of hospitalization, and valuable to the patient's health and well-being. Collectively, this information can help optimize overall patient outcomes and minimize unnecessary healthcare spending across the country.

"This is an exciting collaboration for PMC because it closely fits with the data analysis we already undertake for OHCA on pharmaceutical utilization and outcomes," said Terry Cothran, R.Ph., PMC director. Projects will be jointly managed by PMC and Amgen, with PMC performing research services funded by Amgen.

"Leveraging our collaborative research experience and population health unit, Amgen is excited to engage in our first partnership with a state Medicaid agency to evaluate and gain insights on Medicaid health plan data. Through this unique partnership, we look forward to working with OHCA and PMC to apply that information in identifying opportunities, including value-based programs, to improve costs, quality of care and the patient experience in Oklahoma," said Peter Juhn M.D., M.P.H., vice president of Global Value-Based Partnerships at Amgen.

Globally, Amgen is engaged in over 75 distinct, value-based projects, spanning disease state collaborations, risk sharing, cost-cap programs, and outcomes-based agreements. The company has more than 25 ongoing partnerships in the United States and has several other collaborations under development.

About the Oklahoma Health Care Authority (OHCA)

OHCA administers two health programs for the state. The first is SoonerCare, Oklahoma's Medicaid program. SoonerCare works to improve the health of qualified Oklahomans by ensuring that medically necessary benefits and services are available. Qualifying Oklahomans include certain low-income children, seniors, the disabled, those being treated for breast or cervical cancer and those seeking family planning services. The second program OHCA operates is Insure Oklahoma, which assists qualifying adults and small business employees in obtaining health care coverage for themselves and their families. Currently, there are 814,806 Oklahomans enrolled in OHCA's programs. The agency contracts with a state-wide network of 46,449 providers.

About Pharmacy Management Consultants

Pharmacy Management Consultants, managed by the University of Oklahoma College of Pharmacy, provides operational, consultant and educational services to OHCA through a professional services contract with the University of Oklahoma College of Pharmacy. These services primarily support OHCA in its administration of pharmacy benefits to Oklahoma SoonerCare members and in its efforts to meet Federal OBRA requirements related to Drug Utilization Review.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...